Development and validation of a phosphorylated SMAD ex vivo stimulation assay

Biomarkers

Volumn 12, Issue 3, 2007, Pages 313-330

  Farrington, D L ^a   Yingling, J M ^a   Fill, J A ^a   Yan, L ^a   Qian, Y W ^a   Shou, J ^a   Wang, X ^a   Ehsani, M E ^a   Cleverly, A L ^a   Daly, T M ^a   Lahn, M ^a   Konrad, R J ^a   Ray, C A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Cancer; Ex vivo stimulation; LY2157299; pSMAD; TGF receptor I kinase inhibitor; tSMAD

Indexed keywords

BIOLOGICAL MARKER; SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; DOWNSTREAM PROCESSING; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; LIGAND BINDING; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; VALIDATION STUDY;

ACTIVIN RECEPTORS, TYPE I; ANIMALS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CELL LINE, TUMOR; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MICE; MICE, NUDE; NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RATS; RATS, INBRED F344; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; REPRODUCIBILITY OF RESULTS; SMAD PROTEINS; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34247617701     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.1080/13547500601162441     Document Type: Article

References (23)

1. Bible, KC, Lensing, JL, Nelson, SA, Lee, YK, Reid, JM, Ames, MM, Isham, CR, Piens, J., Rubin, SL and Rubin, J. (2005) Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clinical Cancer Research, 11, pp. 5935-5941.
2. Dudley, RA, Edwards, P., Ekins, RP, Finney, DJ, McKenzie, IG, Raab, GM, Rodbard, D. and Rodgers, RP. (1985) Guidelines for immunoassay data processing. Clinical Chemistry, 31, pp. 1264-1271.
3. Feng, XH, Lin, X. and Derynck, R. (2000) Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15(Ink4B) transcription in response to TGF-b. EMBO Journal, 19, pp. 5178-5193.
4. Goldsby, RA, Kindt, TJ and Osborne, BA (2000) Kuby Immunology, W.H. Freeman and Company, New York
5. Lagna, G., Hata, A., Hemmati-Brivanlou, A. and Massague, J. (1996) Partnership between DPC4 and SMAD protein in TGF-b signaling pathways. Nature, 383, pp. 832-836.
6. Lawrence, LW (1992) The phagocytic leukocytes-morphology, kinetics, and function. Clinical Hematology: Principles, Procedures, Correlations, pp. 292-302. J.B. Lippincott Publishers, Philadelphia
7. Lee, JW, Devanarayan, V., Barrett, YC, Weiner, R., Allinson, J., Fountain, S., Keller, S., Weinryb, I., Green, M. and Duan, L. (2006) Fit-for-purpose method development and validation for successful biomarker measurement. Pharmaceutical Research, 23, pp. 312-328.
8. Lorusso, PM, Adjei, AA, Varterasian, M., Gadgeel, S., Reid, J., Mitchell, DY, Hanson, L., DeLuca, P., Bruzek, L. and Piens, J. (2005) Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. Journal of Clinical Oncology, 23, pp. 5281-5293.
9. Massague, J. (1996) TGFβ signaling: Receptors, transducers, and Mad proteins. Cell, 85, pp. 947-950.
10. Massague, J. and Chen, YG (2000) Controlling TGF-b signaling. Genes & Development, 14, pp. 627-644.
11. Mead, AL, Wong, TT, Cordeiro, MF, Anderson, IK and Khaw, PT (2003) Evaluation of anti-TGF-b2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Investigative Ophthalmology & Visual Science, 44, pp. 3394-3401.
12. Nakao, A., Imamura, T., Souchelnytskyi, S., Kawabata, M., Ishisaki, A., Oeda, E., Tamaki, K., Hanai, J., Heldin, CH and Miyazono, K. (1997) TGF-b receptor-mediated signaling through Smad2, Smad3 and Smad4. EMBO Journal, 16, pp. 5353-5362.
13. Peralba, JM, DeGraffenried, L., Friedrichs, W., Fulcher, L., Grunwald, V., Weiss, G. and Hidalgo, M. (2003) Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients. Clinical Cancer Research, 9, pp. 2887-2892.
14. Qing, J., Zhang, Y. and Derynck, R. (2000) Structural and functional characterization of the transforming growth factor-b-induced Smad3/c-Jun transcriptional cooperativity. Journal of Biological Chemistry, 275, pp. 38802-38812.
15. Schlingensiepen, KH, Schlingensiepen, R., Steinbrecher, A., Hau, P., Bogdahn, U., Fischer-Blass, B. and Jachimczak, P. (2006) Targeted tumour therapy with the TGF-b2 antisense compound AP 12009. Cytokine Growth Factor Review, 17, pp. 129-139.
16. Shi, Y. and Massague, J. (2003) Mechanisms of TGF-b signaling from cell membrane to the nucleus. Cell, 113, pp. 685-700.
17. Stopa, M., Anhuf, D., Terstegen, L., Gatsios, P., Gressner, AM and Dooley, S. (2000) Participation of Smad2, Smad3, and Smad4 in transforming growth factor b (TGF-b)-induced activation of Smad7. The TGF-b response element of the promoter requires functional Smad binding element and E-box sequences for transcriptional regulation. Journal of Biological Chemistry, 275, pp. 29308-29317.
18. Uhl, M., Aulwurm, S., Wischhusen, J., Weiler, M., Ma, JY, Almirez, R., Mangadu, R., Liu, YW, Platten, M. and Herrlinger, U. (2004) SD-208, a novel transforming growth factor b receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Research, 64, pp. 7954-7961.
19. Wick, W., Naumann, U. and Weller, M. (2006) Transforming growth factor-b: A molecular target for the future therapy of glioblastoma. Current Pharmaceutical Design, 12, pp. 341-349.
20. Wrana, JL, Attisano, L., Carcamo, J., Zentella, A., Doody, J., Laiho, M., Wang, X-F and Massague, J. (1992) TGFβ signals through a heteromeric protein kinase receptor complex. Cell, 71, pp. 1003-1014.
21. Wrana, JL, Attisano, L., Wieser, R., Ventura, F. and Massague, J. (1994) Mechanism of activation of the TGF-b Receptor. Nature, 370, pp. 341-347.
22. Yingling, JM, Blanchard, KL and Sawyer, JS (2004) Development of TGF-b signaling inhibitors for cancer therapy. Nature Review Drug Discovery, 3, pp. 1011-1022.
23. Zhang, Y., Feng, X-H, Wu, R-Y and Derynck, R. (1996) Receptor-associated Mad homologues synergize as effectors of the TGF-b response. Nature, 383, pp. 168-172.